Elevance Health

Current directors and officers who also hold a role at another S&P 500 company.

• Antonio F. NeriHPE · CEO
• Deanna D. Strable-SoethoutPFG · CEO
• Felicia F. NorwoodWFC · Director
• Gail BoudreauxTGT · Director
• Lewis Hay IIILHX · Director
• Robert L. Dixon, Jr.OKTA · Director
• Susan D. DevoreSOLV · Director

Latest Schedule 13D/13G filing per holder. Holders that reported falling below 5% are not shown. Index funds usually report once a year.

No 5% holder filings parsed yet for this company.

Open-market purchases and sales reported on Form 4. Grants, option exercises and tax withholding are excluded.

Every 8-K with Item 5.02 (departure, election or appointment of directors and officers). The text is the first paragraph of the item.

1. Feb 26, 2026

   On February 26, 2026, Elevance Health, Inc. (the “Company”) announced certain management changes. Among these changes, Peter D. Haytaian will transition from his role as Executive Vice President and President of Carelon, effective May 4, 2026, to devote more time to family commitments. Mr. Haytaian will serve the Company as Special Advisor through December 31, 2026, to support an orderly leadership transition and ensure continuity across Carelon’s operations and client and partner relationships. Mr. Haytaian’s decision is not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. A copy of the press release dated February 26, 2026, is furnished as Exhibit 99.1 to this report.

   Read the 8-K filing
2. Dec 10, 2025

   On December 10, 2025, the Board of Directors (the “Board”) of Elevance Health, Inc. (the “Company”) elected Amy W. Schulman to serve as an independent director effective January 12, 2026, with a term expiring at the Company’s 2028 annual meeting of shareholders. The Board also appointed Ms. Schulman to its Audit and Finance Committees. There is no arrangement or understanding between Ms. Schulman and any other person pursuant to which she was elected to the Board, and Ms. Schulman has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K of the Securities Exchange Act of 1934, as amended. The Board has determined that Ms.

   Read the 8-K filing
3. Jul 28, 2025

   On July 28, 2025, the Board of Directors (the “Board”) of Elevance Health, Inc. (the “Company”) elected Steven H. Collis to serve as an independent director effective August 1, 2025, with a term expiring at the Company’s 2027 annual meeting of shareholders. The Board also appointed Mr. Collis to the Audit and Finance Committees of the Board. There is no arrangement or understanding between Mr. Collis and any other person pursuant to which he was elected to the Board, and Mr. Collis has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K of the Securities Exchange Act of 1934, as amended. The Board has determined that Mr. Collis qualifies as an “audit committee financial expert” as defined in the Securities and Exchange Commission regulations. Mr.

   Read the 8-K filing
4. Aug 8, 2023

   On August 8, 2023, Elevance Health, Inc. (the “Company”) announced that Mark Kaye has been named Executive Vice President and Chief Financial Officer (“CFO”) of the Company, effective November 1, 2023 (the “Transition Date”). Mr. Kaye will commence employment with the Company on September 6, 2023 as CFO Designate prior to assuming the CFO position on the Transition Date. Mr. Kaye succeeds John Gallina, who, after nearly thirty years of dedicated services to the Company, has decided to retire as CFO. Mr. Gallina will continue to be employed by the Company in the new role of Special Advisor to the Chief Executive Officer from the Transition Date. Mr. Kaye, age 44, joins the Company from Moody’s Corporation, where he served as the Executive Vice President and Chief Financial Officer since April 2021 and as Senior Vice President and Chief Financial Officer from August 2018 to April 2021.

   Read the 8-K filing
5. Feb 22, 2023

   Elevance Health, Inc. (the “Company”) is today announcing that Gloria M. McCarthy will assume the new role of Special Advisor to the Chief Executive Officer and will no longer serve as Executive Vice President and Chief Administrative Officer of the Company, effective April 1, 2023.

   Read the 8-K filing
6. Oct 25, 2022

   On October 24, 2022, the Board of Directors (the “Board”) of Elevance Health, Inc. (the “Company”) elected Deanna Strable-Soethout to serve as an independent director effective November 1, 2022, with a term expiring at the Company’s 2023 annual meeting of shareholders. The Board also appointed Ms. Strable-Soethout to the Audit and Governance Committees of the Board. There is no arrangement or understanding between Ms. Strable-Soethout and any other person pursuant to which she was elected to the Board, and Ms. Strable-Soethout has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K of the Securities Exchange Act of 1934, as amended. The Board has determined that Ms. Strable-Soethout qualifies as an “audit committee financial expert” as defined in the Securities and Exchange Commission regulations. Ms.

   Read the 8-K filing
7. Aug 4, 2021

   On August 3, 2021, the Board of Directors (the “Board”) of the Company elected Susan Dodson DeVore to serve as an independent director effective immediately, with a term expiring at the Company’s 2022 annual meeting of shareholders. The Board also appointed Ms. DeVore to the Audit and Finance Committees of the Board. There is no arrangement or understanding between Ms. DeVore and any other person pursuant to which she was elected to the Board, and Ms. DeVore has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K of the Securities Exchange Act of 1934, as amended. The Board has determined that Ms. DeVore qualifies as an “audit committee financial expert” as defined in the Securities and Exchange Commission regulations. Ms.

   Read the 8-K filing
8. Oct 1, 2019

   On October 1, 2019, the Board of Directors (the “Board”) of the Company elected Ryan Schneider to serve as an independent director effective immediately, with a term expiring at the Company’s 2022 annual meeting of shareholders. The Board also appointed Mr. Schneider to the Audit Committee of the Board. There are no arrangements or understandings between Mr. Schneider and any other person pursuant to which he was elected to the Board, and Mr. Schneider has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K of the Securities Exchange Act of 1934, as amended. Mr.

   Read the 8-K filing
9. May 10, 2018

   On May 8, 2018, Brian T. Griffin notified Anthem, Inc. (the “Company”) that he is resigning as Executive Vice President of the Company and Chief Executive Officer of IngenioRx,, a subsidiary of the Company, effective as of May 10, 2018. A copy of the Company’s press release announcing Mr. Griffin’s resignation is furnished with this report on Exhibit 99.1. Section 9—Financial Statements and Exhibits

   Read the 8-K filing
10. Jan 31, 2018

    On January 30, 2018, the Board of Directors (the “Board”) of the Company elected Bahija Jallal to serve as an independent director effective February 1, 2018 with a term expiring at the Company’s 2019 annual meeting of shareholders. The Board also appointed Ms. Jallal to the Compensation and Governance Committees of the Board. There are no arrangements or understandings between Ms. Jallal and any other person pursuant to which she was elected to the Board, and Ms. Jallal has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K of the Securities Exchange Act of 1934, as amended. Ms.

    Read the 8-K filing
11. Dec 7, 2017

    On December 6, 2017, the Board of Directors (the “Board”) of Anthem, Inc. (the “Company”) elected Antonio F. Neri to serve as an independent director effective immediately with a term expiring at the Company’s 2018 annual meeting of shareholders. The Board also appointed Mr. Neri to the Audit Committee of the Board. There are no arrangements or understandings between Mr. Neri and any other person pursuant to which he was elected to the Board, and Mr. Neri has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K of the Securities Exchange Act of 1934, as amended. Mr.

    Read the 8-K filing
12. Nov 6, 2017

    On November 6, 2017, Anthem, Inc. (the “Company”) announced that its Board of Directors (the “Board”) appointed Gail Boudreaux as the Company’s Chief Executive Officer and President, effective November 20, 2017 (the “Transition Date”). The Company also announced that its Board appointed Ms. Boudreaux as a member of the Company’s Board, effective as of the Transition Date, in the class of directors with a term expiring at the 2020 annual meeting of the Company’s shareholders. A copy of the related press release is furnished with this Current Report on Form 8-K as Exhibit 99.1. Ms.

    Read the 8-K filing
13. May 18, 2017

    On May 18, 2017, the shareholders of Anthem, Inc. (the “Company”) approved the 2017 Anthem Incentive Compensation Plan (the “Plan”). The Plan is described in Proposal 6 in the Company’s definitive proxy statement for the 2017 Annual Meeting of Shareholders, filed with the Securities and Exchange Commission on March 31, 2017 (the “2017 Proxy Statement”), which description is incorporated herein by reference. The descriptions of the Plan contained herein and incorporated by reference from the 2017 Proxy Statement are qualified by reference to the full text of the Plan, a copy of which is filed herewith as Exhibit 10.1 and incorporated herein by reference.

    Read the 8-K filing
14. May 4, 2016

    Director or officer change (Item 5.02). Open the filing for details.

    Read the 8-K filing

Proxy statements (DEF 14A): 2026 · 2025 · 2024 · 2023 · 2022 · 2021

From the company's 10-K XBRL data (SEC companyfacts).

People who stopped filing as an insider of this company. “Last filing” is the last Form 3/4/5, an upper bound on when they left.